{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-042849","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2022-11-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.490891+00:00","generated_at":"2026-06-21T13:42:55.694761+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eterna Therapeutics receives Nasdaq deficiency notice for insufficient stockholders' equity","bullets":["Stockholders' equity ~$8.8M as of Sep 30, 2022, below $10M minimum for Nasdaq Global Market.","Company has 45 days to submit a compliance plan; Nasdaq may grant up to 180-day extension.","Company may also consider transferring its listing from Nasdaq Global Market to Nasdaq Capital Market.","Notice has no immediate effect on listing; delisting risk if compliance not regained within prescribed timeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-042849","json":"https://secwatch.observer/filing/0001140361-22-042849.json","markdown":"https://secwatch.observer/filing/0001140361-22-042849.md","text":"https://secwatch.observer/filing/0001140361-22-042849.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036122042849/0001140361-22-042849-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036122042849/brhc10044625_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T13:42:55.694761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3421abf6a4f21cdba765b791cfe9fea438d258bd","claim":"Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).","evidence_excerpt":"November 22, 2022, Eterna Therapeutics Inc. (the “ Company ”) received a notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company’s stockholders’ equity of approximately $8.8 million, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, fails to comply with the minimum $10.0 million stockholders’ equity requirement for continued listing on the Nasdaq Global Market in accordance with Nasdaq Listing Rule 5450(b)(1)(A) (the “ Nasdaq Listing Rule ”). The Notice has no immediate effect on the listing of the Com","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122042849/0001140361-22-042849-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5450(b)(1)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}